S erum high density lipoprotein (HDL) cholesterol
and apolipoprotein A-I (apo A-I) concentrations are associated with atherogenesis and coronary heart disease.
1 " 3 The risk factor status of triglycerides may be stronger than previously assumed. 4 ' 5 Dietary supplementation with fish oils rich in polyunsaturated fatty acids (PUFAs) of the n-3 family consistently lowers serum triglycerides, but the effects on HDL cholesterol and apo A-I have varied. 6 - 10 High doses of fish oil may lower both HDL cholesterol and apo A-I levels. 7 After moderate doses of n-3 PUFAs, however, an increase in the HDL cholesterol level was accompanied by a decrease in the apo A-I level. 8 " 10 It is assumed that eicosapentaenoic (EPA; 20:5n-3) and docosahexaenoic (DHA; 22:6n-3) acids are the active agents mediating the metabolic effects of n-3 PUFAs. 6 Significant associations between the fall in plasma triglyceride values and the increase in plasma levels of both EPA and DHA have been reported in human studies. 11 However, in vitro studies with cultured cells 1213 and the perfused rat liver 14 indicate that EPA and DHA may have different effects on the hepatic synthesis or release of triglycerides. It is presently not known whether HDL cholesterol and apo A-I are similarly associated with the dietary intake or the plasma phospholipid content of the different n-3 PUFAs.
In this article we examine the alterations in serum lipid, lipoprotein, and apolipoprotein levels after dietary supplementation with a concentrated formula containing EPA and DHA. We also examine the relation between the changes in serum lipid or lipoprotein concentrations and plasma phospholipid fatty acid levels by using multivariate analysis to assess the possible separate effects of EPA and DHA. We have previously reported that blood pressure in this study group was lowered after fish oil intake. hundred fifty-six men and women aged 34-60 years were recruited from a population health survey conducted in Troms0, Norway. The subjects were healthy as determined by medical history, clinical examination, laboratory tests, and electrocardiography. They had not previously used lipid-lowering or antihypertensive drugs. The study was approved by the regional board of research ethics, and each subject gave written consent. The study began with a 6-month observational period, during which the subjects were asked to continue their usual diet and living habits and to visit the clinic for measurement of various parameters on three occasions. All participants had a serum total cholesterol level between 5.2 and 10.0 mmol/1 and a diastolic blood pressure between 85 and 110 mm Hg on each occasion.
After the observational period the participants were randomly assigned to receive fish oil or corn oil and were entered into a 10-week, double-blind, dietary supplementation trial. The fish oil group was given 6 g 85% ethyl ester EPA and DHA (K85, Norsk Hydro, Oslo, Norway) per day, which provided 3.3 and 1.8 g per day of EPA and DHA, respectively. The corn oil group received 6 g corn oil per day with 3.4 g linoleic (18: 2n-6) acid. The oils were given in indistinguishable soft gelatin capsules, each of which contained 1 g fatty acids and 3-4 IU a-tocopherol as an antioxidant. Either supplement provided approximately 2% of the mean daily energy intake and <6 mg cholesterol per day. The exact composition of the supplements has been previously reported. 15 Participants were questioned about side effects and intercurrent diseases. Compliance was assessed by capsule counts, measurements of plasma phospholipid fatty acid concentrations, and estimation of the intake of nutrients from unannounced 24-hour dietary recalls recorded by a registered dietitian. 15 
Measurements
Fasting venous blood samples were obtained at the beginning and the end of the intervention period. Plasma and serum samples were stored at -80°C until the study was completed and were analyzed before the randomization code was broken. The concentrations of plasma phospholipid fatty acids were measured as previously described, 15 and the results were quantified in weight percent (the fatty acid in question as a percentage of total phospholipid fatty acids). Serum total cholesterol was measured with an enzymatic colorimetric method (CHOD-PAP), HDL cholesterol was measured in a similar fashion after precipitation with phosphotungstic acid and magnesium chloride, 16 and triglycerides (in fresh serum) were determined by enzymatic hydrolysis and subsequent measurement of the liberated glycerol by colorimetry (GPO-PAP). The kits were purchased from Boehringer-Mannheim, Mannheim, FRG. The methods were calibrated using Seronorm Lipid (Nycomed, Oslo, Norway). Low density lipoprotein (LDL) cholesterol was calculated using the formula LDL cholesterol=total cholesterol-HDL cholesterol -(triglycerides x 0.47) when triglyceride is <4.5 mmol/1. 17 Concentrations of apo A-I and apo B were measured by immunoturbidimetry on a Behring Nephelometer (Behringwerke AG, Marburg, FRG) using antibodies and standards from the manufacturer.
Statistical Analysis
Change was calculated as the value obtained at the end minus the value obtained at the beginning (baseline) of intervention and was tested for statistical significance by one-sample and two-sample t tests. Linear associations were evaluated by testing Pearson correlation coefficients and multiple linear regression analyses, with the change in serum lipid or lipoprotein concentration as the dependent variable and the changes in plasma phospholipid fatty acids as independent variables. Corresponding one-way analyses of covariance (ANCOVA) were run with quintiles of EPA or DHA as the grouping variable. The assumptions of the multivariate analyses were confirmed by residual analysis and computation of influence statistics. 18 Neither the SEM nor other indexes indicated the presence of moderate or severe collinearity in the analysis. 18 The tests are two tailed throughout. The SAS software package was used. 19 All 156 participants completed the study. Data for plasma fatty acids in five subjects were unavailable. Two subjects were treated with corticosteroids during the trial, and three subjects had febrile infectious diseases and were treated with antibiotics at baseline or during the study. These 10 subjects were not included in the analysis, which is therefore based on 146 subjects. Inclusion of all participants in the analysis did not notably alter the results. Two nonfasting participants were not included in the triglyceride or LDL cholesterol analyses. The number of observations ranged from 138 to 146 because of missing data.
Results
Sixty-one percent of the participants were men, and 37% were smokers. The age was 49±7 years (mean±SD), and the body mass index was 26.0±3.3 kg/m 2 . Systolic and diastolic blood pressures were 144.3±12.7 and 94.9±6.6 mmHg, respectively. The groups assigned to receive fish oil or corn oil were well balanced at baseline (Tables 1 and 2) . 15 Overall adherence to the study protocol was satisfactory. Ten and seven subjects in the fish oil and corn oil groups, respectively, reported that they did not take the prescribed number of capsules, frequently because of self-limited mild or moderate abdominal discomfort.
In the fish oil group the mean dietary intake of EPA and DHA increased from 0.37 to 3.35 g per day and from 0.65 to 2.32 g per day, respectively, whereas dietary linoleic acid (9.3 g per day) did not change. In the corn oil group the intake of linoleic acid increased from 8.7 to 11.3 g per day, whereas the intake of EPA and DHA fell from 0.35 to 0.16 g per day (p=0.013) and from 0.63 to 0.35 g per day (p=0.019), respectively. Dietary intake of saturated or monounsaturated fat and protein and alcohol consumption did not change in either group. Dietary carbohydrate intake decreased in the corn oil group (-ll%;/?=0.002) but not in the fish oil group. Body weight increased by 0.70 kg in the fish oil group and 0.56 kg in the corn oil group (both/7<0.01); the difference was not significant. 
Serum Lipids and Lipoproteins
Serum triglyceride values fell by 0.30 mmol/1 (95% confidence interval [CI], -0.41 to -0.19) in the fish oil group in contrast with no change in the corn oil group (Table 1) . HDL cholesterol levels rose by 0.05 mmol/1 (95% CI, 0.01-0.09) after fish oil intake and by 0.08 mmol/1 (95% CI, 0.03-0.12) after corn oil intake. Apo A-I levels did not change during fish oil supplementation. In the corn oil group, however, apo A-I levels rose by 0.06 g/1 (95% CI, 0.02-0.10), in parallel with HDL cholesterol. Baseline levels of serum triglycerides and HDL cholesterol were inversely correlated (r=-0.43, p=0.0001), but there was no association between changes in these variables during fish oil (r=-0.09) or corn oil (r= -0.05) supplementation.
Plasma Phospholipid Fatty Acids
The total amount of plasma phospholipid fatty acids did not change during fish oil or corn oil supplementation. 15 In the fish oil group, plasma phospholipid EPA and DHA levels rose at the expense of n-6 PUFAs and monounsaturated fatty acids (Table 2 ). In the corn oil group the level of n-6 PUFAs rose and the level of n-3 PUFAs fell; the fall in n-3 PUFAs was correlated with the decrease in dietary n-3 PUFAs (r=0.28, p=0.016). The change in plasma phospholipid EPA and DHA levels was correlated during both fish oil (r=0.67) and corn oil (r=0.49) supplementation. There was no correlation between the change in alcohol consumption or body weight and the change in plasma phospholipid EPA or DHA content in the fish oil or the corn oil group (data not shown).
Relation Between Changes in Plasma Phospholipid Eicosapentaenoic or Docosahexaenoic Acid and Serum Lipid and Lipoprotein Levels
Triglycerides. There were significant correlations in the fish oil group between the fall in serum triglyceride level and the increase in the plasma phospholipid content of both EPA (r=-0.30) and DHA (r=-0.27) (both p<0.05). The corresponding coefficients in the corn oil group were r=-0.11 and r=-0.08 (both p=NS). The change in EPA (/>=0.035) but not DHA (p=0.5) was inversely associated with a change in serum triglycerides when both fatty acids were included simul- taneously as predictor variables in the multiple linear regression analysis (pooled analysis, n = 144).
High density lipoprotein cholesterol. In the fish oil group there was a positive association between the rise in HDL cholesterol and plasma phospholipid EPA levels (r=0.33, /?=0.006), whereas HDL cholesterol and plasma phospholipid DHA levels did not correlate (Figure 1) . Surprisingly, in the corn oil group there was a strong inverse relation between the change in HDL cholesterol and plasma phospholipid DHA levels (r=-0.43, p=0.0002), whereas HDL cholesterol and EPA did not correlate. In the multivariate analysis EPA showed a positive relation with HDL cholesterol (/?=0.064 in the corn oil group); in contrast, DHA and HDL cholesterol were inversely correlated ( Table 3) . The multivariate analysis gave a notable increment in R 2 compared with the bivariate analyses (see "Appendix"). The slope for the change in DHA versus the change in HDL cholesterol was significantly (/><0.01) steeper in the corn oil than the fish oil group. A squared term for DHA was significant in the pooled data (Table 3) . Controlling for the variability in triglyceride levels during the study did not notably alter the relation between the change in EPA or DHA and HDL cholesterol (data not shown).
Of the individual plasma phospholipid fatty acids shown in Table 2 , only changes in EPA and DHA contributed significantly to an explanation of the variability in HDL cholesterol during the study (Table 4) .
Apolipoprotein A-I. There was a significant inverse relation between the change in serum apo A-I and plasma phospholipid DHA levels in the fish oil group (r= -0.28, p=0.017) and the corn oil group (r=-0.51, p=0.0001) (Figure 1 ). In contrast, apo A-I and plasma phospholipid EPA levels were not bivariately associated. The multiple regression analysis strengthened the inverse relation between DHA and apo A-I, whereas EPA showed a consistent positive relation to apo A-I (Table 3 ). The multivariate analysis gave a better fit to the data than the bivariate analysis (see "Appendix"), as indicated by the increment in R 2 . The slope for the change in DHA versus the change in apo A-I was slightly steeper in the corn oil group than the fish oil group; a squared term for the change in DHA contributed weakly (p=0.064) to/? 2 in the pooled data (Table 3 and Figure 2 ). The significance of the squared term was weakened (p=0.15) when an outlying observation ( Figure 2) was deleted from the analysis, indicating an essentially linear relation between the change in plasma phospholipid DHA and serum apo A-I levels in the pooled data. The same pattern was found in both sexes as well as in smokers and nonsmokers (data not shown).
The inverse relation between the changes in DHA and apo A-I still remained significant after accounting for the variability in HDL cholesterol level (by ANCOVA with the change in HDL cholesterol as the covariate) ( Figure  3 ). In contrast, the change in EPA did not correlate with apo A-I when controlling for HDL cholesterol. Table 2 Changes in the levels of plasma phospholipid oleic (18:ln-9) (positively), nervonic (24:ln-9), and arachidonic (20: 4n-9) (both inversely) acids were also related to serum apo A-I concentrations (Table 4) , but these fatty acids did not much alter the slope for the change in DHA or EPA versus apo A-I (data not shown). When introduced in the regression as the last variable, DHA and EPA accounted for 44% and 17%, respectively, of the explained variability in apo A-I.
The observed difference in serum apo A-I concentration during corn oil and fish oil supplementation (0.08 g/1; /?=0.014) ( Table 1) not alter the observed difference in apo A-I between the corn oil and the fish oil groups (data not shown).
Apolipoprotein B and low density lipoprotein cholesterol. Changes in plasma phospholipid EPA or DHA content were not associated with changes in apo B or LDL cholesterol levels in either group (data not shown). In the pooled data, changes in EPA (r=0.17,p=0.054) and DHA (r=0.19,/>=0.028) were marginally correlated with changes in LDL cholesterol concentrations.
Discussion
Participants in the present study consumed a relatively high amount of n-3 PUFAs from fish in their usual diet. It is likely that the fall in the level of plasma phospholipid n-3 PUFAs in the corn oil group reflected both the decrease in the dietary intake of fish as well as the competition between linoleic acid and n-3 PUFAs for the 2 position in the phospholipid molecules. 20 The fall in plasma phospholipid erucic acid also suggests that fish consumption was lowered during corn oil supplementation. 21 The opposite trends for n-3 PUFAs in the corn oil and fish oil groups, therefore, made it possible to study serum lipoprotein levels in relation to changes in plasma phospholipid EPA or DHA levels over a wide range of values in a randomized study.
The major new observation reported here was the divergent association between the change in plasma phospholipid DHA or EPA content and the change in serum HDL cholesterol and apo A-I levels. It is unlikely that the results can be explained by the play of chance. The validity of the findings is further supported by the similar trends observed in the fish oil and corn oil groups as well as the subgroups defined by gender or smoking status. It is unlikely that alcohol consumption or body weight could have confounded the results because EPA or DHA was not associated with these variables. The fish oil supplement provided more EPA than DHA, but the results obtained in the corn oil group indicate that the effects were not caused by different dosages of the two fatty acids.
The present data do not establish the mechanism(s) for the difference between EPA and DHA. At least two categories of mechanisms may be considered. In the first case, phospholipid molecular species containing EPA or DHA may be differently enriched in the various blood lipid and lipoprotein fractions 22 without being causally related to the cholesterol or protein content of the lipoproteins. In the second case, EPA and DHA may have disparate causal effects on the HDL cholesterol and/or the apo A-I level.
In this study DHA appeared to be more closely related than EPA to apo A-I. DHA accounted for a greater amount of the variability in apo A-I than did EPA, and the observed difference in the apo A-I level between the fish oil and corn oil groups was removed after standardizing for the variability in plasma phospholipid DHA. It may be suggested that DHA itself or a factor associated with DHA influences synthesis or catabolism of apo A-I. Dietary n-3 fatty acids have been reported to suppress the synthesis of apo A-I in the rat liver and intestine, 23 but that study did not report the results for individual n-3 fatty acids. Apo A-I, the major protein of the HDL particle, is believed to play an important role in plasma cholesterol transport by acting as an activator of lecithin:cholesterol acyltransferase (LCAT). 24 HDL may originate as "nascent HDL" particles containing apo A-I and phospholipids as bilayer discs formed in the liver and the intestine or may originate from the surface coat of lipolyzed triglyceride-rich lipoproteins. 25 Nascent HDL is thought to grow into mature spherical HDL particles by incorporating into a hydrophobic core the cholesteryl esters derived from the LCAT reaction. 25 LCAT is apparently also involved in the interconversion of HDL 2 and HDL3. 25 Fish oil may lower plasma LCAT activity.
11
There is evidence that LCAT shows substrate specificity for fatty acid molecular species and that phospholipids containing DHA may be a poorer acyl-chain donor to the LCAT reaction than are phospholipid molecules with EPA, linoleic acid, or oleic acid in the 2 position.
-

26
- 27 It is suggested that higher amounts of phospholipid DHA may interfere with the transformation of nascent HDL to spherical HDL and/or that they may alter the distribution of HDL 2 and HDL3, possibly by modulating the LCAT reaction. Phospholipid-apo A-I bilayer discs and nascent HDL may be more easily cleared from the plasma than are mature HDL particles, 2528 which could lead to a depletion of plasma apo A-I at higher levels of phospholipid DHA. Fish oil has been reported to increase the larger, less dense HDL 2 1011 ' 29 and to decrease the smaller, denser HDL3. 29 Changes in HDL size or core lipid composition may also influence apo A-I catabolism. 30 Decreased synthesis or increased catabolism of apo A-I would be expected to lower HDL cholesterol levels 2530 and could account for the inverse correlation between plasma phospholipid DHA and HDL cholesterol levels in the present study. Although the majority of plasma apo A-I is associated with HDL, other lipoproteins also contain some apo A-I, and there is also a "free" plasma pool of apo A-I. 31 We observed that DHA and apo A-I remained correlated after statistical control for HDL cholesterol, whereas EPA was not related to apo A-I after standardizing for HDL cholesterol ( Figure 3 ). The present data are consistent with the hypothesis that the relation between DHA and HDL cholesterol is a consequence of a relation between DHA and apo A-I and that EPA and HDL cholesterol may be related through other mechanism(s).
The fall in serum triglyceride concentrations after fish oil intake probably depends on decreased hepatic very low density lipoprotein (VLDL) triglyceride synthesis and/or secretion. 12 -14 Experiments with cultured liver cells 13 and the perfused rat liver 14 indicate that EPA lowers hepatic secretion of triglycerides to a greater extent than does DHA. The present data support these results, as EPA but not DHA remained associated with triglycerides in the multivariate analysis. Could the association between EPA and HDL cholesterol be secondary to an effect of EPA on triglyceride production? Measurements of the production rates of VLDL triglyceride have provided no evidence that HDL cho- lesterol is influenced by VLDL synthesis in humans. 32 In the present data there was no correlation between the changes in triglyceride and HDL cholesterol levels, and controlling for the variability in triglycerides failed to modify the relation between EPA (or DHA) and HDL. These results suggest that the association between n-3 PUFAs and HDL is not a consequence of their hypotriglyceridemic effects. Accelerated exchange of HDL core cholesteryl ester for VLDL and/or chylomicron core triglyceride via lipid transfer protein has been proposed as a mechanism for the low plasma HDL cholesterol levels in hypertriglyceridemia. 33 Fish oil may lower lipid transfer protein activity, 11 thereby retaining more cholesteryl esters within HDL. Lipid transfer protein may show specificity for fatty acid molecular species, 34 but we are unaware of any studies that have examined whether EPA and DHA modulate lipid transfer protein activity differently.
Appendix
In summary, the present data indicate a major difference between EPA and DHA in relation to both the cholesterol and the apolipoprotein content of the HDL particle. Further studies using purified fatty acid formulas are needed to determine whether these relations represent causality and to define the underlying mechanisms.
